Page last updated: 2024-11-12
eremantholide c
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
eremantholide C: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 20835084 |
CHEBI ID | 181266 |
MeSH ID | M0518071 |
Synonyms (9)
Synonym |
---|
(1s,3r,7z,9r,12s,13r,15r)-13-hydroxy-3,7,12-trimethyl-13-prop-1-en-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione |
CHEBI:181266 |
69883-97-2 |
eremantholide c |
6,9-epoxy-2h-1,4-dioxacyclodeca(cd)pentalene-2,7(4ah)-dione, 2a,3,5,6,11a,11b-hexahydro-3-hydroxy-2a,6,10-trimethyl-3-(1-methylethenyl)-, (2as-(2ar*,3s*,4ar*,6s*,10z,11as*,11bs*))- |
6,9-epoxy-2h-1,4-dioxacyclodeca(cd)pentalene-2,7(4ah)-dione, 2a,3,5,6,11a,11b-hexahydro-3-hydroxy-2a,6,10-trimethyl-3-(1-methylethenyl)-, (2as,3r,4as,6r,10z,11ar,11br)- |
nsc 669146 |
DTXSID801099426 |
(2as,3r,4as,6r,10z,11ar,11br)-2a,3,5,6,11a,11b-hexahydro-3-hydroxy-2a,6,10-trimethyl-3-(1-methylethenyl)-6,9-epoxy-2h-1,4-dioxacyclodeca[cd]pentalene-2,7(4ah)-dione |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
furofuran | Organic heterobicyclic compounds containing a two furan rings ortho-fused to each other. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |